Marksans Pharma Share Price: fresh 52-week high analysis
NiveshIQ
NSE: MARKSANS · Pharma
Marksans Pharma Ltd.
₹329.40▼ ₹1.00 (-0.30%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on MARKSANS. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Marksans Pharma Ltd.
Marksans Pharma Limited, headquartered in Mumbai, focuses on research, manufacturing, and marketing of a broad range of pharmaceutical formulations across pain management, cardiovascular, CNS, anti‑diabetic, gastrointestinal, and dermatology segments. The company’s product mix includes tablets, capsules, oral liquids, ointments, creams, and liquids, supplied to supermarkets, pharmacy chains, and wholesalers worldwide. In FY2023, Marksans generated ₹3,172 Cr in revenue and ₹517 Cr in net income, reflecting a 12% YoY revenue growth and a 15% increase in net profit. Recent developments include a fresh 52‑week high in share price, expansion plans targeting Europe as a new growth engine, and participation in investor dialogues such as Ashwamedh and Elara India. Competitively, Marksans leverages
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,177 Cr +17.50% | ₹2,623 Cr +20.50% | ₹2,951 Cr +12.50% |
| EBITDA Margin | 21.08% | 20.63% | 23.16% |
| Net Profit | ₹315.00 Cr +18.90% | ₹383.00 Cr +21.60% | ₹420.06 Cr +9.70% |
| EPS | ₹6.93 | ₹8.40 | ₹9.22 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Marksans Pharma Share Price: fresh 52-week high analysis
Marksans Pharma: Europe- The Next Growth Engine!
🔒
+ 3 more stories about Marksans Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹841 Cr, PAT ₹159 Cr, EPS ₹3.47, EBITDA margin 28.4%. Growth context: revenue YoY +1272.1%, PAT YoY -99.7%, revenue QoQ -1.8%, PAT QoQ +7.0%. Street verdict: inline, revenue surprise -1.1%, PAT surprise +6.6%.
Product pipeline delivery, domestic demand, export mix, approvals, and margin discipline remain the key forward drivers ...
FY26 (last completed FY): revenue ₹2, 951 Cr, PAT ₹420 Cr, EBITDA margin 23.2%, EPS ₹9.22. Year-on-year: revenue YoY +12...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for MARKSANS
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track MARKSANS alongside your other holdings
Unlock full MARKSANS research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Marksans Pharma Ltd.?
NiveshIQ detects active intelligence signals for Marksans Pharma Ltd. (MARKSANS) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Marksans Pharma Ltd.?
Marksans Pharma Ltd. operates in the Pharma sector with a market capitalisation of ₹1,129,601.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.